σ-1 receptor (S1R) radioligands have the potential to detect and monitor various neurological diseases. Herein we report the synthesis, radiofluorination, and evaluation of a new S1R ligand 6-(3-fluoropropyl)-3-(2-(azepan-1-yl)ethyl)benzo[d]thiazol-2(3H)-one ([(18)F]FTC-146, [(18)F]13). [(18)F]13 was synthesized by nucleophilic fluorination, affording a product with >99% radiochemical purity (RCP) and specific activity (SA) of 2.6 ± 1.2 Ci/μmol (n = 13) at end of synthesis (EOS). Positron emission tomography (PET) and ex vivo autoradiography studies of [(18)F]13 in mice showed high uptake of the radioligand in S1R rich regions of the brain. Pretreatment with 1 mg/kg haloperidol (2), nonradioactive 13, or BD1047 (18) reduced the binding of [(18)F]13 in the brain at 60 min by 80%, 82%, and 81%, respectively, suggesting that [(18)F]13 accumulation in mouse brain represents specific binding to S1Rs. These results indicate that [(18)F]13 is a promising candidate radiotracer for further evaluation as a tool for studying S1Rs in living subjects.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4106900 | PMC |
| http://dx.doi.org/10.1021/jm300371c | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
F-18 FDG PET/CT based Preoperative Machine Learning Prediction Models for Evaluating Regional Lymph Node Metastasis Status of Patients with Colon Cancer.
Asian Pac J Cancer Prev
January 2025
Department of Nuclear Medicine, Busan Paik Hospital, University of Inje College of Medicine, Busan, Republic of Korea.
Objective: This study aimed to develop a simple machine-learning model incorporating lymph node metastasis status with F-18 Fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) and clinical information for predicting regional lymph node metastasis in patients with colon cancer.
Methods: This retrospective study included 193 patients diagnosed with colon cancer between January 2014 and December 2017. All patients underwent F-18 FDG PET/CT and blood test before surgery.
Cognitive variation reflects amyloid, tau, and neurodegenerative biomarkers in Alzheimer's disease.
Geroscience
January 2025
Psychology, School of Social Sciences, Nanyang Technological University, 48 Nanyang Avenue S639818, Singapore, Singapore.
In Alzheimer's disease (AD), the accumulation of neuropathological markers such as amyloid-β plaques, neurofibrillary tangles, and cortical neurodegeneration occurs over many years before overt manifestation of cognitive impairment. There is thus a need for neuropsychological markers that are indicative of pathological changes in the early stages of the disease. Intra-individual cognitive variability (IICV), defined as the variation of an individual's performance across cognitive domains, is a promising neuropsychological marker measuring heterogeneous changes in cognition that may reflect these early pathological changes.
View Article and Find Full Text PDFHighly specific amyloid and tau PET ligands for ATN classification in suspected Alzheimer's disease patients.
Ann Nucl Med
January 2025
Department of Radiological Sciences, School of Health Science, Fukushima Medical University, 10-6 Sakae, Fukushima City, Fukushima, 960-8516, Japan.
Objective: This study aims to accurately classify ATN profiles using highly specific amyloid and tau PET ligands and MRI in patients with cognitive impairment and suspected Alzheimer's disease (AD). It also aims to explore the relationship between quantified amyloid and tau deposition and cognitive function.
Methods: Twenty-seven patients (15 women and 12 men; age range: 64-81 years) were included in this study.
Purpose: We hypothesised that applying radiomics to [F]PSMA-1007 PET/CT images could help distinguish Unspecific Bone Uptakes (UBUs) from bone metastases in prostate cancer (PCa) patients. We compared the performance of radiomic features to human visual interpretation.
Materials And Methods: We retrospectively analysed 102 hormone-sensitive PCa patients who underwent [F]PSMA-1007 PET/CT and exhibited at least one focal bone uptake with known clinical follow-up (reference standard).
Diagnostic value of 11C-Methionine PET-CT imaging in persistent or recurrent Cushing's disease after surgery.
J Clin Endocrinol Metab
January 2025
Department of Endocrinology and Nutrition, Cliniques Universitaires Saint-Luc UCL, Bruxelles, Belgium.
Introduction: Equivocal or negative pituitary magnetic resonance imaging (MRI) findings raise a significant challenge in the management of persistent or recurrent Cushing's disease (CD), compromising the chances of success of a further transsphenoidal surgery (TSS). The aim of our study was to determine the diagnostic utility of 11C-methionine (MET) positron emission tomography coupled with computerized tomography (PET/CT) in localizing the residual or relapsing corticotroph adenoma.
Methods: We retrospectively analyzed the results of 11C-MET PET/CT performed in two tertiary medical centers between May 2002 and November 2023 in 22 patients with a persisting or recurrent CD after initial TSS and equivocal or negative pituitary MRI findings.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!